Broad antiviral and anti‐inflammatory efficacy of nafamostat against SARS‐CoV‐2 and seasonal coronaviruses in primary human bronchiolar epithelia

Antiviral strategies that target host systems needed for SARS‐CoV‐2 replication and pathogenesis may have therapeutic potential and help mitigate resistance development. Here, we evaluate nafamostat mesylate, a potent broad‐spectrum serine protease inhibitor that blocks host protease activation of t...

Descripción completa

Detalles Bibliográficos
Autores principales: Niemeyer, Brian F., Miller, Caitlin M., Ledesma‐Feliciano, Carmen, Morrison, James H., Jimenez‐Valdes, Rocio, Clifton, Clarissa, Poeschla, Eric M., Benam, Kambez H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8441815/
https://www.ncbi.nlm.nih.gov/pubmed/34541574
http://dx.doi.org/10.1002/nano.202100123

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8441815/
https://www.ncbi.nlm.nih.gov/pubmed/34541574
http://dx.doi.org/10.1002/nano.202100123

Ejemplares similares